Glut of Ph.D.'s? Consider Pharmaceutical Sciences

The Commission of Life Sciences of the National Research Council (NRC) issued a report (September 1998), Trends in the Early Careers of Life Scientists, stating that the university system is producing a surplus of Ph.D.s. (P. Smaglik, E. Russo, The Scientist, 12[19]:6, Sept. 28, 1998). Since there are not enough permanent positions for the new Ph.D.s, they are relegated to take one postdoctoral position after another, ending up being frustrated and earning a less-than- satisfactory salary for

Written byGordon Amidon
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The Commission of Life Sciences of the National Research Council (NRC) issued a report (September 1998), Trends in the Early Careers of Life Scientists, stating that the university system is producing a surplus of Ph.D.s. (P. Smaglik, E. Russo, The Scientist, 12[19]:6, Sept. 28, 1998). Since there are not enough permanent positions for the new Ph.D.s, they are relegated to take one postdoctoral position after another, ending up being frustrated and earning a less-than- satisfactory salary for their intellect and highly trained skills. The observation of NRC was based on the finding that about 62 percent of Ph.D.s five to six years after graduation held a permanent job in 1995 as compared to 89 percent in 1973 (www.nap.edu/readingroom/books/trends/).

Similar inferences were drawn from a survey by the American Society for Cell Biology (www.faseb.org/ascb/pubpol/careersnwsrel.htm) indicating that it is tougher and tougher to pursue a career in biomedical sciences. It took an ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies